(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The 10 Most Compelling Forerunners in Innovation - 2Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- 3Share your pick for the tree that you love for its novel magnificence!
- 4Finding the Universe of Workmanship: Individual Encounters in Imagination
- 5Changing Negative Cash Mentalities: Enabling Your Monetary Excursion
- Which Kind of Pet Makes the Incomparable Buddy?
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- A Manual for Well known Western television Series
- ‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa
- German politician urges more face-to-face interaction in digital age
- Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- Catch the moon dancing with bright star Regulus tonight
- Step by step instructions to Keep up with Great Hand Cleanliness Before Handshakes
- Step by step instructions to Show Children the Significance of Appropriate Handshaking
